Africa is facing a growing cancer crisis, with the annual burden of disease expected to reach 2.4 million new cases and 1.6 million deaths by 2045. BVGH unites African governments and healthcare leaders; biotechnology and pharmaceutical companies; and academic oncology experts to address key drivers of Africa’s cancer crisis holistically and sustainably.

Putting Into Perspective

Cancer In Africa

Cancer mortality in the USA is

decreasing.

Cancer mortality in Africa is

increasing.

Mortality

2.5

out of 10 cancer patients in the USA will die

6.4

out of 10 cancer patients in Africa will die

85%

of children with cancer in the USA will live

90%

of children with cancer in Africa will die

Contributing Factors

Low ratio of trained oncologists to patients

Limited resources for diagnosis and treatment

Lack of community awareness

Our Cancer Programs

Two doctors consult over a file in a hospital reception room.

African Access Initiative (AAI)

Africa’s cancer burden is fueled by disparities in access to quality oncology care. Without intervention, experts predict that by 2030, one million people in Africa will die from cancer annually. Driven by Africa, for Africa, the African Access Initiative (AAI) takes an innovative, holistic approach to strengthening cancer care ecosystems. Using data generated at the country level by African hospitals and governments, and engaging international biotechnology and pharmaceutical companies as key partners, AAI is:

Expanding sustainable access to cancer medicines and technologies.
Building clinical oncology capacity.
Addressing the cancer data gap in Africa through clinical trials.
Expanding awareness of cancer in Africa.

Learn More about AAI

African Consortium for Cancer Clinical Trials (AC³T)

A lit microscope sits in the foreground with a researcher pipetting liquid onto a microscop slide.

Under the purview of AAI, BIO Ventures for Global Health (BVGH) launched the African Consortium for Cancer Clinical Trials (AC³T) to foster and implement cancer clinical trials led by investigators in Africa. AC³T is designed to build clinical trial capacity and address the cancer data gap in Africa, while increasing access to prioritized cancer diagnostics, medicines, and quality treatment for African cancer patients. AC³T will bring together AAI partners and key stakeholders to leverage cross-sector capabilities and empower African clinicians to implement cancer clinical trials in Africa.

Learn More about AC³T